Phase 1 pilot RCT in 38 men with mild-to-moderate psoriasis: balinatunfib vs placebo for 4 weeks caused no serious or severe adverse events (primary safety outcome), but more dysgeusia (61.5% vs 0%) and nausea (19.2% vs 0%). Target lesion scores improved more.
RCTn = 38
Nassr et al. Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis